Fluicell AB is a biotechnology company based in Mölndal that specializes in tissue therapeutics. The company has developed the Nexocyte™ tissue therapeutics platform, which focuses on bioengineering and cancer interception. This platform enables the advancement of innovative solutions aimed at cancer treatment, utilizing cutting-edge technologies in the field of biotechnology.
In addition to its core offerings, Fluicell AB provides single-cell spatial transcriptomic profiling, which allows for detailed analysis at the cellular level. The company is actively engaged in research and development initiatives and collaborates with various researchers and partners to further its objectives. Fluicell AB also participates in exclusive global licensing agreements, enhancing its reach and impact within the biotechnology sector.